Market revenue in 2024 | USD 694.1 million |
Market revenue in 2030 | USD 1,008.5 million |
Growth rate | 6.5% (CAGR from 2025 to 2030) |
Largest segment | Surgery |
Fastest growing segment | Drug Based |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Based, Surgery |
Key market players worldwide | GlaxoSmithKline Consumer Healthcare (GSK CH India), GlaxoSmithKline, Pfizer Inc, Novartis AG ADR, Biogen Inc, H. Lundbeck AS Class A, Cadila Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neuralgia treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 68.81% in 2024. Horizon Databook has segmented the Europe neuralgia treatment market based on drug based, surgery covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe neuralgia treatment market, including forecasts for subscribers. This continent databook contains high-level insights into Europe neuralgia treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account